EPMC Pharm
EPMC Pharma is committed to bringing the best adapted treatments to the European market for neonatal children, whether as part of a consortium, under our own commercial initiative or with other pharmaceutical or biotech companies.
Sucrose 24%
Why EPMC?
With several medicines in the pipeline, our first in-line product is ‘Sucrose 24%’, an aqueous sterile oral solution used as a complement to medicines and other treatments for pain in the neonate.
Innovating for success
Cutting-edge product driven by innovation
EPMC Pharma is committed to bringing the best adapted treatments to the European market for neonatal children, whether as part of a consortium, under our own commercial initiative or with other pharmaceutical or biotech companies
Request a Demo arrow_forwardSucrose 24%
0{{current_slide_index}} | 0{{total_slide_count}}
Sucrose 24%
EPMC Pharma is committed to bringing the best adapted treatments to the European market for neonatal children, whether as part of a consortium, under our own commercial initiative or with other pharmaceutical or biotech companies. With several medicines in the pipeline, our first in-line product is ‘Sucrose 24%’, an aqueous sterile oral solution used as a complement to medicines and other treatments for pain in the neonate.
We'd Love To Hear From You
Request a Demo
Find us Here
- barkt 13
- industry zone, cesaera